ROCALTROL
What it isActive 1,25-dihydroxyvitamin D requiring no renal hydroxylation; CKD mineral bone disorder and hypoparathyroidism.
Why it mattersIt bypasses the failing kidney, which cholecalciferol cannot, and acts within hours rather than weeks.
What it changesHypercalcemia is the limiting toxicity and needs monitoring. Its short half-life means the effect is quickly lost, and quickly reversed in overdose.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Dialysis patients (renal osteodystrophy) | Adults | 0.25 mcg QD | 0.5–1 mcg QD | |
| Hypoparathyroidism / pseudohypoparathyroidism | Adults & children ≥6y | 0.25 mcg QAM | 0.5–2 mcg QD | |
| Hypoparathyroidism | Children 1–5y | 0.25–0.75 mcg QD | 0.25–0.75 mcg QD | |
| Predialysis patients | Adults & children ≥3y | 0.25 mcg QD | up to 0.5 mcg QD | 0.5 mcg QD |
| Predialysis patients | Children <3y | 10–15 ng/kg/day | 10–15 ng/kg/day |
Titration Dialysis: 4–8 week intervals; hypoparathyroidism and predialysis: 2–4 week intervals between increases
Renal Dosed per renal/dialysis status (see indications)
Hepatic Undefined
Pregnancy Pregnancy Category C; teratogenic in rabbits at high doses; use only if benefit justifies fetal risk
Lactation Undefined
NO BOXED WARNINGS
Principal riskHypercalcemia
Cost, est. cash$10–$300/month
Generic entry2001
Legacy pregnancy categoryUnknown / historical label unavailable
Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.

Open Calcitriol in the interactive console ↗
